Drug Trial Radar · NCT05372718
Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
170
Actual
Start
Dec 26, 2022
Primary completion
Sep 30, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Supergene, LLCIndustry
- Sponsor type
- Industry
- First posted
- May 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Objective: to evaluate the efficacy and safety of intra-arterial intrathrombus administration of the recombinant non-immunogenic staphylokinase (Fortelyzin®) in patients with acute limb ischemia (ALI) vs surgery.
Conditions
- Acute Limb Ischemia
Interventions
Recombinant non-immunogenic staphylokinase (Fortelyzin®)Drug
lyophilisate for preparation a solution
surgical methods of treatmentProcedure
Endovascular intervention, open surgery and/or bypass surgery in accordance with the current National Guidelines
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients without amputationsTime frame: 30 days post randomization
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Kaliningrad Regional Clinical Hospital
Kaliningrad, Russia
Kazan City Hospital No. 7
Kazan', Russia
S.S. Yudin City clinical hospital
Moscow, Russia
S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center
Moscow, Russia
Ufa Emergency City Hospital
Ufa, Russia
Volgograd City Clinical Hospital of Emergency #25
Volgograd, Russia
Kursk city emergency hospital
Kursk, Kursl Region, Russia
Sergiyev Posad Regional Clinical Hospital
Sergiyev Posad, Moscow Oblast, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.